United Kingdom Insulin Market Insight
The United Kingdom Insulin Market is growing at an 5.65%CAGR, driven by rising diabetes prevalence, ageing population, NHS adoption of advanced insulin devices and biosimilars improving glycemic control.
United Kingdom Insulin Market Insights Forecasts to 2035
- The United KingdomInsulin Market Size Was Estimated at USD 872.2Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 5.65% from 2025 to 2035
- The United KingdomInsulin Market Size is Expected to Reach USD 1510.6Million by 2035
Notable Insights for United Kingdom Insulin Market
- By product type, long-acting insulin dominated, accounting for approximately 45–50% share in 2024, due to improved glycaemic stability and reduced dosing frequency.
- By formulation, insulin analogues held approximately 60–65% share, driven by better safety profiles and lower hypoglycaemia risk compared to human insulin.
- Approximately 10–12% of the UK adult population lives with diabetes, creating sustained demand for insulin therapies and delivery systems.
- Around 70–75% of insulin users in the UK prefer pen devices over vials due to ease of use, portability, and improved adherence.
Download the eBook (ToC)
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United Kingdom Insulin Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in United Kingdom Insulin Market
- Novo Nordisk
- Sanofi
- Eli Lilly and Company
- Biocon Biologics
- Pfizer
- AstraZeneca
- Wockhardt
- Ypsomed
- Others
Recent Developments:
- In May 2025, UK researchers supported by Breakthrough T1D UK and University of Birmingham are developing glucose-responsive smart insulin capsules that release insulin only when blood glucose rises, aiming to reduce hypoglycemia risk.
- In February 2025, Once-weekly basal insulins such as insulin icodec and insulin efsitora alfa are advancing through late-stage trials in Type 2 diabetes, aiming to reduce daily injections and improve treatment adherence.
- In January 2025, UK T1D Grand Challenge has announced £2.7 million funding for six projects developing novel insulins, including glucose-responsive and ultra-fast formulations, aimed at improving Type 1 diabetes management and safety outcomes.
Market Segmentation:
United Kingdom Insulin Market, By Product Type
- Rapid-Acting Insulin
- Long-Acting Insulin
- Premixed Insulin
- Intermediate-Acting Insulin
- Others
United Kingdom Insulin Market, By Formulation
- Human Insulin
- Insulin Analogues
- Biosimilar Insulin
United Kingdom Insulin Market, By Delivery Device
- Insulin Pens
- Insulin Pumps
- Syringes & Vials
- Smart Delivery Systems
United Kingdom Insulin Market, By End User
- Hospitals & Clinics
- Home Care Settings
- Diabetes Clinics
United Kingdom Insulin Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Channels
Expert Views:
The UK Insulin Market is expected to grow steadily due to increasing diabetes prevalence and strong NHS focus on improving long-term glycemic control. Experts highlight insulin pens and biosimilars as key growth drivers, supported by patient preference for convenience and affordability. Advancements in smart insulin delivery systems and integration with digital glucose monitoring are expected to reshape diabetes management, improving outcomes and supporting market expansion through 2035.